Decision Support in Washington

InBios International, Inc. is a privately-held biotechnology company specializing in the design, development, and manufacture of immunodiagnostic devices for infectious diseases and biothreats. Founded in 1996 and headquartered in Seattle, Washington, the company operates a state-of-the-art GMP-compliant, FDA-registered manufacturing facility certified to ISO 13485:2016. InBios maintains a portfolio of over 25 FDA-cleared diagnostic products and extensive life science reagent catalogs. Core offerings include ELISA kits, rapid point-of-care tests, and contract manufacturing services for emerging infectious disease diagnostics. The company delivers immunoassays targeting dengue, West Nile virus, Zika, Chagas disease, leishmaniasis, COVID-19, influenza, and biothreats such as anthrax and melioidosis. InBios provides comprehensive assay development, regulatory affairs support, and contract manufacturing capabilities to clinical laboratories, public health agencies, research institutions, and OEM partners globally. The company is recognized for rapid response to emerging disease threats while maintaining rigorous quality standards and cost-effective solutions for the global diagnostic market.

SeniorLife.AI is an AI-powered wellness platform designed for senior living operators, longevity clinics, concierge medicine practices, and rehabilitation providers. The platform utilizes vision-based artificial intelligence and passive monitoring technologies to predict mobility and cognitive decline risk months to years in advance. Core capabilities include Risk Insights (AI-trained on 4M mobility records and 2.5M cognitive decline cases), Mobility Metrics Tracker (FDA Class II SaMD—30 gait and balance metrics from 30-second smartphone video), Gaze Metrics Analysis (5-minute iPad eye movement test for early cognitive impairment detection), and Dynamic Care Plan (role-specific action synthesis integrated with EHR systems via SMART on FHIR). The platform also features passive 24/7 room radar monitoring and on-demand vitals scanning. Trained on Mayo Clinic records, SeniorLife.AI integrates seamlessly into existing clinical workflows and can be white-labeled via API. The solution targets fall prevention, functional performance tracking, and objective evidence for discharge planning and CMS reimbursement justification in post-acute care settings.

Akili Interactive is a digital medicine company that develops prescription and over-the-counter video game–based treatments for cognitive impairments, particularly ADHD. The company combines neuroscience research with interactive gaming technology to deliver therapeutic interventions through engaging digital experiences rather than traditional pharmaceutical or device-based approaches. EndeavorRx is the company's FDA-authorized prescription digital therapeutic for children with ADHD; EndeavorOTC is a clinically validated over-the-counter game-based treatment for adults with ADHD, available on iOS and Android platforms. Akili's platform represents a novel therapeutic class—digital medicine—designed to improve attention, focus, and quality of life. The company's proprietary technology integrates clinical efficacy data with game design to create accessible, engaging treatment experiences. Products are delivered directly to patients via consumer app stores and through prescription channels, with clinical evidence supporting cognitive improvements in ADHD populations.